hepatitis%20a%20-and-%20e
HEPATITIS A & E

Hepatitis A route of transmission is through oral-fecal route while in hepatitis E, aside from the oral-fecal route, it is also transmitted through blood transfusion in endemic areas.

Hepatitis A incubation period is 15-50 days and hepatitis E incubation period is 15-60 days.

Hepatitis A & E viruses cause epidemics.

 

Hepatitis%20a%20-and-%20e Diagnosis

History

Important Points in the Clinical History of Patients with Suspected Viral Hepatitis

  • Contacts with jaundiced patients
  • IV drug use
  • History of blood transfusion
  • Surgery or hospitalizations
  • Family history of chronic liver disease
  • Occupation
  • Food and water sources

Laboratory Tests

Serological Tests

Hepatitis A

  • Anti-hepatitis A virus (HAV) IgM has high sensitivity and specificity and is a marker of acute infection
    • This test remains positive for ≥6 months
  • Anti-HAV should be tested in patients <50 years

Hepatitis E

  • IgM anti-HEV, IgG anti-HEV in combination with hepatitis E virus (HEV) RNA indicate acute hepatitis E infection
  • Detection of HEV antigen by enzyme immunoassays may also be used to diagnose both acute and chronic infections
  • HEV genotype should be determined, if possible, in all HEV-infected persons prior to treatment to determine type and duration of therapy and chances of response; predominant genotypes worldwide are:
    • Genotype 1: Africa and Asia
    • Genotype 2: Mexico, West Africa
    • Genotype 3: Developed countries
    • Genotype 4: China, Taiwan, Japan

Tests to Rule Out Other Viral Hepatitis

  • Hepatitis B: Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B e antigen (HBeAg)
  • Hepatitis C: Anti-hepatitis C virus (anti-HCV) antibody, HCV RNA test, HCV core antigen
  • Hepatitis D: Anti-hepatitis D virus (anti-HDV) antibody, HDV RNA test
  • Please see Hepatitis B and Hepatitis C disease management charts for further information

Nucleic Acid Amplification Test (NAAT)

  • Eg conventional reverse transcription polymerase chain reaction (RT-PCR), real-time RT-PCR, transcription-mediated amplification methods, genotyping for HAV RNA or HEV RNA may be considered
  • HEV RNA is detected from serum and stool of infected patients by NAAT-based assays

Immunohistochemistry

  • HEV ORF2 protein immunohistochemistry can be used to establish a histopathologic diagnosis of hepatitis E

Other Recommended Lab Tests in Patients Suspected of Viral Hepatitis

  • Liver function tests (LFTs)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
    • Serum bilirubin, alkaline phosphatase (ALP)
  • Prothrombin time (PT), international normalized ratio (INR), complete blood count (CBC) with platelets, renal function tests
  • Noninvasive tests such as the aminotransferase/platelet ratio index (APRI) or FIB4 may be used to assess the degree of hepatic fibrosis when resources are limited prior to initiating HCV therapy
    • Transient elastography may be an option for patients with contraindications to liver biopsy

Evaluation

Features of Hepatic Decompensation

  • Mental dullness, hepatic encephalopathy, bilateral asterixis, ascites, clinical deterioration
  • Serum bilirubin >2.5x upper limit of normal, PT is 3 seconds longer than control or INR >1.5

Biochemical or Clinical Improvement

  • Repeat liver function test and serum/stool HEV RNA detection will show normalization if patient responded to treatment or infection subsided spontaneously
  • Repeat anti-HAV IgM after 1 week may be used to determine if acute or recent infection has resolved
  • Refer to a specialist if tests are still positive for infection and with disease persistence or progression
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.